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Novel role of pancreatic differentiation 2 in
facilitating self-renewal and drug resistance
of pancreatic cancer stem cells
A P Vaz1,5, M P Ponnusamy1,5, S Rachagani1, P Dey1, A K Ganti2,3 and S K Batra*,1,4
1Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA; 2Department of
Internal Medicine, VA Nebraska Western Iowa Health Care System, University of Nebraska Medical Center, Omaha, NE, USA;
3Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
and 4Buffet Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center,
Omaha, NE, USA
Background: Cancer stem cells (CSCs) contribute towards disease aggressiveness and drug resistance. Specific identification of
CSC maintenance genes and targeting can improve the efficiency of currently available treatment modalities. Pancreatic
differentiation 2 (PD2) has a major role in the self-renewal of mouse embryonic stem cells. In the present study, we investigated the
role of PD2 in pancreatic CSCs.
Methods: Characterisation of CSCs and non-CSCs from mouse models, pancreatic cancer cells and human tissues by CSC and
self-renewal marker analysis using confocal assay. Effect of PD2 knockdown in CSCs (after gemcitabine treatment) was studied by
immunoblot and apoptosis assays.
Results: A subpopulation of cells displayed PD2 overexpression in mouse (KrasG12D; Pdx1-Cre and KrasG12D; Trp53R172H/þ ; Pdx1-
Cre) and human pancreatic tumours, which co-express CSC markers. Cancer stem cells exhibited elevated expression of PD2 and
self-renewal markers, such as Oct3/4, Shh and b-catenin. Gemcitabine treatment maintained the CSC population with
simultaneous maintenance of PD2 and CSC marker expression. Knockdown of PD2 in CSCs resulted in reduced viability of cells
and enhanced apoptosis along with abrogated expression of CD133 and MDR2.
Conclusions: Our results suggest that PD2 is a novel CSC maintenance protein, loss of which renders the CSCs more susceptible
to drug-induced cell death.
Stem cells with cancerous properties are widely known as cancer
stem cells (CSCs). These CSCs constitute a small proportion of
the tumour mass and are found within many human tumours
including colon (O’Brien et al, 2007), brain (Singh et al, 2004), breast
(Al-Hajj et al, 2003), prostate (Collins et al, 2005), pancreatic
(Li et al, 2007) and ovarian cancers (Szotek et al, 2006). Although
the existence of CSCs in all tumours is unclear, the quest for CSCs
is still intriguing. For a cell to be designated as a CSC, it must
possess distinctive properties, such as the ability to regenerate
tumours, promote metastasis, cause aggressive cancers and, most
importantly, it should be capable of self-renewal (Reya et al, 2001).
In addition, CSCs through their drug efflux mechanisms can
make the tumour cells resistant to various drugs (Vaz et al, 2013).
Failure to target this particular cell population has made the
current therapeutic strategies inefficient and consequently tumour
recurrence is observed in most patients with advanced stage
cancers even after an initial response to treatment. Therefore,
considerable research efforts have been directed towards the
identification of specific CSC markers in different cancers for
therapeutic targeting.
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To date, several CSC markers such as CD24, CD34, CD44,
CD117, ESA and CD133 have been identified (Al-Hajj et al, 2003;
Szotek et al, 2006; Ma et al, 2007; O’Brien et al, 2007; Ferrandina
et al, 2008). Cancer stem cells exhibit deregulated self-renewal
pathways such as Wnt, Shh and Notch signalling (Reya et al, 2001;
Ivanova et al, 2006; Ponnusamy and Batra, 2008). In this regard,
the importance of our recent finding is that pancreatic differentia-
tion 2 (PD2) functions as a key regulator of self-renewal in mouse
embryonic stem cells (mESCs) through interaction with Oct3/4
(Ponnusamy et al, 2009). In our previous study, a novel PD2 gene
(accession number AJ401156) was identified in the 19q13.2
amplicon of pancreatic cancer cells via differential screening
analysis (Moniaux et al, 2006). Later, it was discovered that PD2 is
the human homologue of the yeast RNA polymerase II-associated
factor 1 and is part of the human PAF (hPAF) complex, which
consists of other subunits, namely hLeo1, hCtr9, parafibromin/
hCdc73 and hSki8 (Zhu et al, 2005; Moniaux et al, 2006). Further,
our study revealed that the overexpression of this gene in the
immortalised NIH3T3 cells led to the oncogenic transformation of
these cells (Moniaux et al, 2006). In addition, our previous studies
also demonstrated the specific roles of PD2/Paf1 in cell cycle
progression and chromatin structure remodelling in pancreatic
cancer cells (Moniaux et al, 2009; Dey et al, 2011).
In the present study, we demonstrated the novel role of PD2 in
CSC maintenance. Our results demonstrate specific expression of
PD2 in CSC populations of pancreatic cancer after characterisation
of the CSC phenotype by in vitro and in vivo analysis.
Furthermore, isolated CSCs were found to exhibit drug resistance,
which is impaired upon knockdown of PD2 with simultaneous
alteration in the CSC phenotype, and reduction in CD133 and
MDR2 gene expression. Overall, these results suggest that PD2 may
have a role in self-renewal and drug resistance of CSCs.
MATERIALS AND METHODS
Genetically engineered pancreatic cancer animal model. Mouse
pancreatic cancer progression models were developed by crossing
different transgenic mice (KrasG12D, Pdx1-Cre and Trp53R172H/þ )
to generate a composite mouse strain carrying the following
genotype: KC: KrasG12D; Pdx-Cre and KPC: KrasG12D; Trp53R172H/þ ;
and Pdx1-Cre. Their contemporary littermate controls were
also generated. The generated composite double-transgenic
(KC: K-rasG12D; Pdx-Cre) animals develop PanINs at 9 weeks of
age and it progresses to advanced stages of cancer between 40 and
50 weeks of age (Rachagani et al, 2012); whereas the triple-
transgenic composite animals (KPC: K-rasG12D; Trp53R172H/þ ;
Pdx1-Cre) develop PanINs at 5 weeks of age and it progresses to
pancreatic ductal adenocarcinoma between 20 and 25 weeks of age.
The KC (40th and 50th weeks) and KPC (20th and 25th weeks)
animals were euthanised and the resected part of the tumour was
used for CSCs isolation and the remaining half was fixed in
formalin for immunohistochemical studies. We confirmed the
presence of tumours by routine hematoxylin and eosin staining
and the tumour sections were processed for immunofluorescence
studies for PD2 and CSC markers expression. Throughout the
experiment, animals were provided with food and water ad libitum
and subjected to a 12-h dark/light cycle. Animal studies were
performed in accordance with the US Public Health Service
‘Guidelines for the Care and Use of Laboratory Animals’ under an
approved protocol by the University of Nebraska Medical Center
Institutional Animal Care and Use Committee.
Cell culture maintenance. Pancreatic cancer (SW1990, MiaPaca
and BxPC3) cell lines were procured from American Type Culture
Collection (ATCC) (Manassas, VA, USA) and cell lines were
propagated in a humidified atmosphere containing 5% CO2 at
37 1C and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
antibiotics (penicillin and streptomycin). After purchase from
ATCC, we have frozen all these cell lines in early passage numbers
to precede the experiments.
Isolation of side population (SP) and non-side population (NSP)
from cancer cell lines. To determine whether pancreatic cancer
cell lines contain candidate CSC populations, Hoechst 33342 dye (a
fluorescent DNA-binding dye) has been used to sort the SP cells by
flow sorting (Szotek et al, 2006). SP cells can actively pump out the
Hoechst 33342 dye, and hence exhibit low fluorescence as
compared with the non-SP cells. As only SW1990 cells showed a
considerable SP, this cell line was used for further studies. In
parallel, verapamil, a calcium channel blocker that reverses the
multidrug resistance, was used to ensure that the isolated cells were
purely SP cells.
CSC-specific culture. Both SP and NSP cells were cultured in
gelatinised tissue culture dishes in a stem cell-specific medium
containing DMEM (GIBCO, Grand Island, NY, USA) and
F12 supplemented with 10% embryonic stem (ES)-specific FBS
(Invitrogen, Carlsbad, CA, USA), L-glutamine (GIBCO), 1000Umlÿ 1
LIF (Sigma, St Louis, MO, USA), bFGF (Invitrogen) and Pen/Strp.
Two different conditions were maintained for both SP and NSP cells.
Initially, we maintained both SP and NSP fractions for 1 day in
10% FBS-containing DMEM media for the cells to acclimatise and
then subsequently replaced it with stem cell-specific medium. We
cultured SP cells in stem cell-specific media and NSP cells in 10%
FBS-containing DMEM media because NSP cells did not grow well
in stem cell-specific conditions initially but it grew well in DMEM
media. Two days before collecting the lysate, the NSP cells were
grown in stem cell-specific media. Hence, NSP and SP cells were
grown in both DMEM and stem cell-specific media to isolate RNA
and protein for further processing.
RNA isolation and RT–PCR. Total cellular RNA was extracted
from SP and NSP cells using the RNAeasy kit (Qiagen, Valencia,
CA, USA) and processed for reverse transcription. The expression
of PD2 and MDR2 was performed by PCR using specific primers
(PD2 FP 50-TTCCTCGGATCAGGCGTCCC-30 PD2 RP 50-CTGG
GACTCAGTCACTGTCACTA-30; MDR2 FP 50-AGGATGGAAG
CTCACCCTTGTGA-30, MDR2 RP 50-GAAAGCTATCACAGTC
CTGATGGCC-30; CD133 FP 50-CAGAGTACAACGCCAAAC
CA-30, CD133 RP 50-AAATCACGATGAGGGTCAGC-30). The
PCR conditions are as follows: initial denaturation step was at
95 1C for 5min, followed by the denaturation step at 95 1C for
1min, primer annealing step at 58 1C for 1min, extension step at
72 1C for 1min, followed by 35 cycles of amplification and the final
extension step at 72 1C for 15min. PCR reaction products were
then separated by electrophoresis using a 2% agarose gel. Gels were
stained using 0.5mgmlÿ 1 of ethidium bromide and illuminated
with UV light. GAPDH was used as an internal control gene.
Knockdown of PD2 using specific siRNA. The human PD2
region was targeted with specific siRNA (sequence 50-AACAG
GUUCGUCCAGUACAAA-30). Synthetic sense and antisense
oligonucleotides (Dharmacon, Lafayette, CO, USA) were annealed
in 100mM potassium acetate, 30mM HEPES-KOH (pH 7.4) and
2mM magnesium acetate for 1min at 90 1C and 1 h at 37 1C and
frozen. Oligonucleotides were transfected into cells with TransIT-
TKO (Mirus, Madison, WI, USA) in accordance with the supplier’s
recommendations. Gemcitabine (2 mM) treatment was carried out
for 20 days on PD2 knockdown and scramble cells.
Immunoblot assay. SP and NSP cells were processed for protein
extraction and western blotting using standard procedures. Briefly,
the cells were washed twice with PBS and lysed in RIPA buffer
(50mM Tris-HCl, pH 7.4; 0.25% Na-deoxycholate; 1mM EDTA;
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Figure 1. Expression of PD2 in double-transgenic mouse pancreatic cancer samples. (A) Overexpression of PD2 along with CD133 and ALDH1 in
the 40th and 50th weeks of Kras-driven mouse pancreatic tumours. The control pancreas showed no expression in ductal cells. The highlighted
box shows the zoomed image of single-cell staining. (B) FACS analysis was performed using Hoechst 33342 staining in Kras-driven mouse PC-
driven cells. Kras;Pdx1Cre animal cells showed 1.7% of SP cells compared with control animals. Confocal images showed the overexpression of
PD2 along with ALDH1 in isolated SP cells compared with NSP cells. DAPI was used as a nuclear counter staining.
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150mM NaCl; 1% NP-40), supplemented with 5mM Na3VO4,
5mM NaF and 1mM phenylmethylsulphonyl fluoride and stored at
4 1C. Subsequently, the cell lysates were spun at 15 000 r.p.m. for
20min at 4 1C and the supernatants were collected. The proteins
were resolved by using 10% acrylamide;bisacrylamide gels and
transferred onto the PVDF membrane. The membranes were
blocked in 5% non-fat dry milk in PBS for at least 1 h and then
incubated with primary antibodies (anti-PD2, anti-Cdc73, anti-Leo1,
anti-Ctr9, anti-Ski8, anti-ALDH1 (aldehyde dehydrogenase 1), anti-
CD133, anti-Oct3/4, anti- Shh and anti-b-actin) (diluted in 3% BSA
in PBS) and left overnight at 4 1C. Then the membranes were
washed (4 10min) with PBST (phosphate-buffered saline and
0.1% Tween 20) at room temperature and probed with 1 : 2000
diluted horseradish peroxidase-conjugated anti-mouse or anti-rabbit
secondary antibodies for 1 h at room temperature and washed
4 10min with PBST. The signal was detected with an ECL
chemiluminescence kit (Thermo Scientific, Waltham, MA, USA).
Immunofluorescence analysis by confocal microscopy. Cells
were plated onto sterile round cover slips (CIR 18-1 Fisher brand
12-545-10, Fisher Scientific International, Hampton, NH, USA)
and grown in 12-well plates for 24 h. Cells were fixed in acetone/
methanol (1 : 1; pre-chilled to ÿ 20 1C) and permeabilised with
0.1% Triton X-100 in PBS. Then the cells were washed in PBS and
blocked with 10% goat serum for 1 h and washed with PBS. Next,
the cells were incubated with primary antibody rabbit-PD2 (1 : 100
in 1 PBS), rabbit-ALDH1 (1 : 100), rabbit-Shh (1 : 100), mouse-
Oct3/4 (1 : 100), rabbit-b-catenin (1 : 300) and rabbit-CD133
(1 : 100) for 1 h for isolated cells and overnight for tissue sections.
The cells and tissue sections were washed with PBST four times
(10min each) and incubated with fluorescent-tagged secondary
antibodies—both FITC and Texas-red tagged (for 30min) at room
temperature and washed four times with PBST. For the tissue
sections, we followed the same procedure as mentioned previously
after removing paraffin using xylene and hydrating the section
using decreasing grades of alcohol (100% to 20%). Finally, cover
slips were mounted with vectashield mounting medium containing
DAPI (VECTOR, Burlingame, CA, USA).
Apoptosis assay. For this assay, a total of 0.5 106 SW1990-SP cells
were seeded per well in a six-well plate. These cells were subjected to
gemcitabine treatment (2mM) for 7 days, followed by a transient
transfection carried out for 72 h using an siRNA specific against PD2,
along with scrambled RNAi. The apoptosis assay was carried out
with these gemcitabine-treated and PD2 knockdown cells and control
cells for 48 h using annexin V-fluorescein isothiocyanate apoptosis
detection kit (Roche Diagnostics, Indianapolis, IN, USA). After 48 h,
the cells were trypsinised, counted and washed with PBS. The level of
apoptosis was measured by annexin V and propidium iodide staining
followed by flow cytometry.
RESULTS
Specific expression of PD2 in mice and human pancreatic
tumour samples. Recent evidence demonstrate that human
pancreatic CSCs express elevated levels of CD133, CD44, CD24,
ESA and ALDH1 markers (Li et al, 2007; Lee et al, 2008;
Ponnusamy and Batra, 2008; Li et al, 2009). In another study, it has
been shown that the KrasG12D model carries self-renewing
pancreatic CSCs (Shankar et al, 2011). Here, we have analysed
the expression of PD2 along with CSC markers (CD133 and
ALDH1) in tumours resected from both (KC: K-rasG12D; Pdx1-Cre
(40th and 50th weeks) and KPC: K-rasG12D; Trp53R172H/þ ;
Pdx1-Cre (20th and 25th weeks)) the mouse models for PC.
Hematoxylin and eosin staining of tumour sections clearly showed
PanINs as well as areas with well-developed tumours compared
with the control pancreas from contemporary littermates of both
KC: K-rasG12D; Pdx1-Cre (40th and 50th weeks) and KPC:
K-rasG12D; Trp53R172H/þ ; Pdx1-Cre (5th, 10th, 15th, 20th and
25th weeks) mouse models (Supplementary Figures 1a and b). We
have clearly observed PD2 overexpression along with CD133 and
ALDH1 markers only in a specific population of cells (Figure 1A)
in 40- and 50-week-old KC mouse samples compared with age-
matched control animals. The specificity of antibodies was
analysed using different conditions of negative controls such as
using only secondary antibody in the absence of primary antibody
and also by swapping secondary antibodies (Supplementary
Figure 1c) in the same KC mouse tumours. Furthermore, cells
overexpressing PD2 also expressed CSC markers (CD133 and
ALDH1) in the triple-transgenic KPC samples (25th week)
compared with the control samples (20th week) (Figure 2). In
addition, we observed 1.7% CSCs in KC tumour samples, whereas
no SP/CSC population was observed in the control samples using
Hoeschst33342 dye staining-based FACS analysis (Figure 1B).
The isolated CSCs from KC tumour samples showed a clear
cobblestone structure, which is a phenotype of CSCs, along with
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Figure 2. Expression of PD2 in triple-transgenic mouse pancreatic
cancer samples. Overexpression of PD2 along with CD133 and ALDH1
in the 25th week of Kras- and p53-driven mouse pancreatic tumours.
Control pancreas (20th week) showed no expression in ductal cells.
The highlighted box is blown up to show the zoomed image of
single-cell staining.
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elevated expression of PD2 and ALDH1 when compared with
control cells (Figure 1B). Furthermore, we have also observed
increased PD2 expression along with ALDH1 in selected cells
within human pancreatic tumour samples (Figure 3A) compared
with control samples. These results suggest that PD2 is specifically
overexpressed in the CSC population.
Isolation and characterisation of SP and NSP cells from
pancreatic cancer cells. Recently, CSCs have been identified as a
minor population of cells within the cancer cell population. They
can be sorted by flow cytometry based on their capacity to efflux
the fluorescent DNA-binding dye, Hoechst 33342. This is owing to
the overexpression of the ABCG2 drug resistance protein, a
characteristic of cancer stem/progenitor cells (Bunting, 2002; Kim
et al, 2002). This population of sorted cells is called the SP and the
remaining population is named NSP. In the present study, we
analysed the SP and NSP cells in pancreatic cancer cell lines
(SW1990, BXPC3 and MiaPaCa) (Supplementary Figure 2a). The
SW1990 pancreatic cancer cell line showed 0.2% of SP cells, isolated
by Hoechst 33342 dye using the FACS sorting method. Other cancer
cell lines (MiaPaCa and BXPC3) showed minimal or no SP
population. In parallel, verapamil (a calcium channel inhibitor that
reverses the multidrug resistance) was used to ensure that the isolated
cells were purely SP cells (Supplementary Figure 2b).
Isolated SP and NSP cells from SW1990 were grown in vitro under
stem cell-specific conditions (details are mentioned in the Materials
and Methods section). SP cells showed tight junctions and circular
colony formation (Supplementary Figure 2c), whereas NSP cells grew
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Figure 3. Expression of PD2 and CSC markers. SP and NSP cells were processed for protein extraction and western blotting using standard
procedures. (A) Overexpression of PD2 in human pancreatic tumours along with ALDH1 in specific cells. Control tumours did not show specific
overexpression of PD2. (B) Western blot analysis showed increased expression of PD2 in isolated SP cells along with cancer stem cell-specific
markers (CD133 and ALDH1) and also the self-renewal marker SHH in SW1990-SP cells compared with NSP cells. b-actin was used as a loading
control. Fold change of band intensity is mentioned in the western blot results. (C) Confocal analysis showed increased expression of PD2 (green)
along with CSC markers (CD133 and ALDH1, red) in SP cells compared with NSP cells (DAPI-nuclear staining). (D) Western blot analysis showed
other PAF complex subunits such as Leo1, Cdc73, Ctr6 and Ski8 did not show any variation of expression in both SP and NSP cells.
BRITISH JOURNAL OF CANCER Role of PD2 in pancreatic cancer stem cells
490 www.bjcancer.com |DOI:10.1038/bjc.2014.152
like differentiated cells. Formation of spherical colonies has been
reported to be a property of stem/progenitor cells and verifies a high
developmental and proliferative potential of SP cells (Engelmann et al,
2008). Interestingly, in our study, we observed an increased number of
larger tumourspheres in SP cells compared with NSP cells in
pancreatic cancer cell line models (data not shown). This confirms
that the isolated SP cells behave like CSCs. Furthermore in vivo
tumorigenicity assays were also carried out to validate the CSCs. We
observed that the SP cells were highly tumorigenic in nature, and
therefore it was used for further analysis (data not shown).
Preferential expression of PD2 and CSC-specific markers in SP
cells. Cancer stem cells have been demonstrated to express several
universal stem cell markers such as CD133, CD44, CD24, ESA
and ALDH1 in different cancers (Ponnusamy and Batra, 2008).
Stem cells and CSCs are known to possess the phenomenal
property of self-renewal, which is maintained by few specific
pathways such as Shh, Wnt and Notch (Ponnusamy and Batra,
2008). These markers were used for the confirmation of the
isolated CSC population. In our recent study, we have shown that
PD2 is aberrantly expressed in mESCs and maintains the self-
renewal process by interacting with Oct3/4 (Ponnusamy et al,
2009). In this study, we analysed PD2 along with CSC markers
such as CD133, ALDH1, Oct3/4 and Shh in both SP and NSP cells
from SW1990 cells. Interestingly, PD2 showed a significantly
elevated expression along with CD133, ALDH1 and Shh in
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Figure 4. Self-renewal markers in isolated SP cells. Confocal analysis showed a set (Shh, Oct3/4 and b-catenin) of self-renewal marker expression in
SW1990-SP cells. The first panel showed the increased expression of Shh (red) along with PD2 (green) in SP cells compared with NSP cells. The
second panel showed the increased expression of Oct3/4 (green) along with PD2 in SP cells compared with NSP cells. The third panel showed the
membrane localisation and increased expression of b-catenin (red) along with PD2 (green) expression. DAPI was used for nuclear staining.
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SW1990-SP cells compared with NSP cells (Figures 3B and C).
Other PAF complex subunits such as Leo1, Cdc73, Ctr9 and
Ski8 did not show any variation of expression in both SP and
NSP cells (Figure 3D). The expression levels of PD2 and ALDH1
were stable up to the third cell passage when maintained under
stem cell-specific conditions (data not shown). This suggests that
when maintained under stem cell-specific conditions, the isolated
CSC population were maintained in the third passage.
Our previous studies have shown the sub-cellular localisation of
PD2 both in the cytoplasm and nucleus (Moniaux et al, 2009; Dey
et al, 2011). These results indicate that PD2 is preferentially
upregulated in the pancreatic cancer SP cells compared with the
NSP. In addition, self-renewal markers Oct3/4, Shh and b-catenin
showed significantly elevated expression in SW1990-SP cells
compared with NSP cells (Figure 4) by confocal immunofluores-
cence analysis.
Drug treatment maintains the CSC population and PD2
expression. Cancer stem cells are the population of cells
responsible for imparting the drug resistance property to solid
tumours, which is leading to tumour recurrence. It has already
been established that drug resistance of CSCs is due to the
expression of ABC transporter glycoproteins, which are capable
of effluxing the drug out of the cell. To investigate their drug
resistance efficiency, we treated SW1990 SP and NSP cells with
2 mM gemcitabine for 20 days. Cell death was observed on drug
treatment in NSP cells, whereas SP cells maintained their circular
colonies and continued to grow even after 4, 10 and 20 days of
treatment (Figure 5A). This suggests that isolated SP cells retain
their drug resistance property. The expression of PD2 was
steadily maintained along with ALDH1 in the gemcitabine
(2 mM)-treated SW1990-SP cells (Figure 5B), suggesting main-
tenance of CSCs upon drug treatment.
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Figure 5. Drug sensitivity of cancer stem cells (SP) and non-cancer stem cells (NSP) on different days of treatment. (A) Gemcitabine (2mM)
treatment was used for 20 days in both SW1990-SP and NSP cells. SP cells grew well with the characteristic stem cell phenotype upon gemcitabine
treatment compared with NSP cells. (B) Western blot analysis showed that the expression of PD2 and ALDH1 is maintained in gemcitabine-treated
SP cells. b-actin was used as a loading control. Fold change of band intensity is mentioned in the western blot results.
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Knockdown of PD2 affects the CSC phenotype. Seven days
of gemcitabine treatment followed by transient knock down
(72 h) of PD2 was carried out in SW1990-SP cells. We transiently
knock down PD2 using siRNA in SP cells and also treated
the knockdown cells with gemcitabine to understand the
role of PD2 in drug resistance of SP cells. Our results showed
that PD2 knockdown in SP cells resulted in a loss of their
CSC phenotype (Figure 6A), leading to apoptosis (SP-SCR-RNAi:
18.8% and SP-PD2-RNAi: 30.1%) on gemcitabine treatment
(Figure 6B). Further, analysis of PD2, CSC and drug-resistant
markers in gemcitabine-treated PD2 knockdown SP cells
resulted in impaired CSC marker (CD133) and drug-resistant
gene (MDR2) expression compared with control cells
(Figure 6C). These results indicate that PD2 is involved in the
maintenance of the CSC population and controlling the drug
resistance process.
DISCUSSION
Cancer stem/initiating cells have the potential to propagate the
tumour and may be accountable for cancer development,
progression, metastasis and tumour relapse. Identification of
specific molecules that maintain CSCs and targeting these
molecules will therefore provide us with an important tool to
combat cancer. The central study in this paper is to investigate the
expression and role of PD2 in pancreatic CSCs. The specific
overexpression of PD2 along with CSC markers in tumours
resected from genetically engineered models for pancreatic cancer
suggest that PD2 may be an important molecule in CSCs. Cancer
stem cells with their self-renewal property were recently shown in a
Kras-driven pancreatic tumour mouse model (Shankar et al, 2011).
The nature of these CSCs isolated using Hoechst 33342 dye was
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Figure 6. Knockdown of PD2 with drug treatment in SP cells. (A) Seven days of gemcitabine treatment followed by transient knockdown (72 h) of
PD2 was carried out in SW1990-SP cells. Knockdown of PD2 with simultaneous gemcitabine treatment in cancer stem cells (SP) decreased the
viability of SP cells and changed its phenotype. (B) FACS-apoptosis analysis with annexin V and propidium iodide staining showed an increased
percentage of cell death (30.1%) in PD2 knockdown SP cells along with gemcitabine treatment compared with control cells (18.8%). (C) RT–PCR
results showed that knockdown of PD2 downregulates the levels of CD133 and the multidrug resistance 2 (MDR2) gene. Western blot results
showed a decrease in the expression of CD133 protein in PD2 knockdown cells. GAPDH and b-actin served as an expression control. Fold change
of band intensity is mentioned in the RT–PCR and western blot results.
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confirmed using in vitro tumorsphere assays and in vivo animal
assays (data not shown). There are many well-established methods
that demonstrate the isolation of CSCs from different cancers using
Hoechst 33342 dye and surface markers (Al-Hajj et al, 2003;
Collins et al, 2005; Dean et al, 2005; Szotek et al, 2006; Dalerba
et al, 2007; Mimeault et al, 2007; Engelmann et al, 2008; Ferrandina
et al, 2008; Ponnusamy and Batra, 2008; Marsden et al, 2009). The
main limitation of using Hoechst dye is its toxicity to cells; but if
the concentration and incubation time has been standardised
toxicity to cells could be minimised. Small differences in cell
densities, dye concentrations and staining timings may affect the
phenotype of the SP cells. Despite these limitations, we preferred to
use the Hoechst 33342 dye exclusion assay as it overcomes the
barrier of using diverse CSC markers for isolation.
PD2 is a newly discovered self-renewal stem cell factor in mESCs
(Ponnusamy et al, 2009) and is involved in the self-renewal process
by interacting with the ESC marker Oct3/4 (Ponnusamy et al, 2009).
It is well established that self-renewal is a common and important
property of all types of stem cells including CSCs (Reya et al, 2001;
Dalerba et al, 2007; Ponnusamy and Batra, 2008). Similarly, other
groups have shown that knockdown of PAF complex proteins alter
the ESC fate (Ding et al, 2009). Though PD2 is a member of the
hPAF complex, it works exclusively (independent of the other
subunits) in mESC maintenance (Ponnusamy et al, 2009). The
recent report on PD2 in mESCs has shown that the heterozygous
knockout of PD2 in mESCs had no effect on the expression level of
other PAF components; however, their expression was altered when
a homologous knockdown of both PD2 alleles was performed in the
NIH3T3 cells (Ponnusamy et al, 2009). This indicates that
there is synchronised activity of PD2 in differentiated cells as
opposed to the desynchronised activity of PD2 in undifferentiated
cells such as stem cells.
Our earlier studies have demonstrated that PD2 is significantly
overexpressed in poorly differentiated pancreatic cancer cells
compared with well-differentiated cells (Moniaux et al, 2006). In
the present study, we correlated the expression of PD2 with the
maintenance of the CSC population isolated from pancreatic cancer
cells. The expression of PD2 was found to be significantly enriched
in SP cells isolated from pancreatic cancer cells; however, other PAF
complex subunits did not show any variation in expression in SP
cells. This suggests that PD2 has a role independent to the PAF
complex. Similarly, in our previous study we have shown that the
PAF complex is not involved in coordinated events in mESCs
(Ponnusamy et al, 2009). Further, the analysis of stem cell-specific
markers (ALDH1, CD133 and CD44) was correlated with PD2
expression, suggesting that isolated SP cells maintain the cancer
stem-like characters. In addition, the analysis of self-renewal
markers Oct3/4 and Shh showed an increased level of expression
in isolated SP cells compared with NSP cells. This in parallel with
PD2 overexpression prompts us to propose that this molecule may
be involved in the self-renewal process of CSCs.
The complete mechanism(s) of drug resistance and tumour
relapse, as well as the expression of different genes involved in drug
resistance and their regulation in CSCs still remains to be
elucidated. Understanding the underlying mechanism would
provide considerable insight for combating CSCs’-associated drug
resistance in different cancers. It has been reported that breast
cancer patients undergoing chemotherapy exhibit an increase
in the percentage of CD44þCD24–/low cancer cells due
to the chemoresistance property of cancer-initiating cells
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Figure 7. Schematic illustration for the role of PD2 in CSCs. The isolated cancer stem cells by flow sort method were analysed for the
tumorigenicity and tumourspheres formation. Isolated CSC populations overexpress PD2 and maintain the self-renewal and drug resistance
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(Zhou et al, 2009). Similarly, in PC patients, the CD44þCD24þ
cell population increases due to chemotherapy (Jimeno et al, 2009).
Gemcitabine is a nucleoside analogue that is widely used as a
chemotherapeutic agent to treat several cancers and is presently the
most effective agent against pancreatic cancer. In our study,
gemcitabine-treated SP cells survived for 20 days in contrast to the
NSP cells, suggesting that the isolated SP population retained their
drug resistance property. The expression of PD2 and ALDH1, a
drug resistant and CSC-specific marker, was also maintained in SP
cells during the period of drug treatment. However, a transient
knockdown of PD2 in the SP cells results in increased apoptosis
and reduced self-renewal markers’ expression was observed. This
suggests that PD2 may also be involved in the process of drug
resistance in the CSC population. As downregulation of PD2 also
showed a reduced expression of other markers such as CD133 and
MDR2, this suggests that PD2 is involved in the maintenance of
the CSC population and imparts drug resistance. A recent study in
our laboratory showed colocalisation of PD2 with MLL1 (mixed
lineage leukaemia 1), a histone methyltransferase required for
MDR regulation (Huo et al, 2010; Dey et al, 2011). As MDR genes
are critical in conferring drug resistance, the probable involvement
of PD2 in regulating the expression of these MDR genes, either
directly (chromatin enrichment) or indirectly (using MLL1) have
generated great interest and warrant further investigation.
In conclusion, the CSC/SP fraction maintains tumorigenesis and
the drug resistance property along with an enriched expression of
PD2 and other CSC-specific markers (ALDH1, CD133 and CD44)
and self-renewal markers (Oct3/4 and Shh). Furthermore, the
inhibition of PD2 leads to a loss of the CSC phenotype and
decreased expression of CD133 and MDR2. Although other CSC
markers exist, PD2 stands out as a novel marker owing to its ability
to maintain the cellular morphology, drug resistance and self-
renewal property of CSCs (Figure 7). Future studies need to dissect
the mechanism behind the regulation of drug resistance and self-
renewal genes by PD2. Overall, our study suggests that PD2 has an
important role in the maintenance of CSCs and is also involved in
drug resistance. Most importantly, the identification of CSCs with
the specific maintenance marker PD2 would provide critical
information for advancing towards the long-term goal of
developing novel therapeutic strategies to reduce the incidence of
tumour recurrence in cancer patients.
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